<DOC>
	<DOCNO>NCT01518907</DOCNO>
	<brief_summary>This study evaluate safety , effectiveness , pharmacokinetics , immunogenicity AA4500 increase dos concentration treatment adult woman cellulite .</brief_summary>
	<brief_title>The Safety , Effectiveness , Pharmacokinetics AA4500 Treatment Edematous Fibrosclerotic Panniculopathy ( Commonly Known Cellulite )</brief_title>
	<detailed_description />
	<mesh_term>Edema</mesh_term>
	<criteria>Be female ≥ 21 year age ≤ 60 year age Have skin type classification I V accord Fitzpatrick scale Have EFP within posterolateral thigh ( ) and/or buttock ( ) least 12 month screen visit Have photonumeric cellulite severity scale ( CSS ) score ≥ 7 represent moderate severe cellulite severity within right left buttock right leave posterolateral thigh ( select quadrant ) Have area EFP within select quadrant least 8 cm x 10 cm ( ie , target EFP area ) suitable treatment : The target EFP area must locate posterolateral thigh within buttock involve gluteal fold The target EFP area must evident subject standing , without use manipulation skin pinch muscle contraction ( ie , CSS Classification E score 2 3 ) screen injection Have Body Mass Index ( BMI ) 20.0 33.0 kg/m2 , intend maintain stable body weight throughout duration study ( variation ≤5 % baseline body weight permit ) Be willing refrain use artificial tanning device lotion 2week period screen throughout duration study Be willing apply sunscreen sun protection factor ( SPF ) ≥15 select quadrant exposure sun participate study ( ie , screen Day 90 ) Be judge good health , base upon result medical history , physical examination , laboratory profile screen Have negative urine pregnancy test screen injection AA4500 use effective contraception method ( ie , abstinence , intrauterine device [ IUD ] , hormonal [ estrogen/progestin ] contraceptive , barrier control ) least one menstrual cycle prior study enrollment duration study , surgically sterile , postmenopausal female ( menses least 1 year hysterectomy ) Be willing able cooperate requirement study include requirement confinement period throughout study Voluntarily sign date inform consent agreement approve Institutional Review Board/Independent Ethics Committee/Human Research Ethics Committee ( IRB/IEC/HREC ) . The subject must also sign authorization form allow disclosure protect health information ( PHI ) . The PHI authorization form inform consent form may integrate form may separate form depend institution Be able complete understand various rating instrument English Has follow condition : Thyroid disease , unless control medication ≥ 6 month Uncontrolled diabetes mellitus , determine investigator Uncontrolled hypertension , determine investigator Vascular disorder ( eg , phlebitis varicose vein ) area treat Lipedema lymphatic disorder History low extremity thrombosis postthrombosis syndrome Documented autoimmune disorder lupus erythematosus , rheumatoid arthritis Inflammation active infection area treat Cutaneous alteration area treat Rash , eczema , psoriasis , skin cancer area treat History keloidal scar abnormal wound heal Coagulation disorder ; take anticoagulant ( except ≤ 150 mg aspirin daily ) 7 day prior injection day Known active hepatitis B C ( history hepatitis A permit ) Known immune deficiency disease positive test human immunodeficiency virus ( HIV ) Other significant condition include body dysmorphic disorder , investigator 's opinion would make subject unsuitable enrollment study Has use follow treatment EFP legs buttock intend use follow time study : Liposuction time injection AA4500 Injections ( eg , mesotherapy ) ; radiofrequency device treatment ; laser treatment ; surgery ( include subcision ) within 12 month injection AA4500 Endermologie similar treatment within 6 month injection AA4500 Massage therapy within 3 month injection AA4500 Creams prevent mitigate EFP within 2 week injection AA4500 Has tattoo quadrant select treatment Is presently nursing baby provide breast milk baby Intends become pregnant study Intends initiate intensive sport exercise program study Has unrealistic expectation treatment outcome , determine investigator Has positive alcohol breath test and/or positive urine drug screen amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , methadone , opiates , and/or propoxyphene screen Day 1 Has receive investigational drug treatment within 30 day injection AA4500 Has know systemic allergy collagenase excipient AA4500 Has receive collagenase treatment within 30 day treatment Has , time , receive AA4500</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>cellulite</keyword>
	<keyword>Xiaflex</keyword>
</DOC>